Alnylam Pharmaceuticals
ALNY
226 hedge funds and large institutions have $6.95B invested in Alnylam Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 76 increasing their positions, 64 reducing their positions, and 22 closing their positions.
136% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 22
65% more capital invested
Capital invested by funds: $4.22B → $6.95B (+$2.73B)
19% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 64
14% more funds holding
Funds holding: 198 → 226 (+28)
11% more call options, than puts
Call options by funds: $90.2M | Put options by funds: $81.5M
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0.29% less ownership
Funds ownership: 95.64% → 95.35% (-0.29%)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$160M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$52.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$46.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$42.6M |
Top Sellers
| 1 |
SPC
Slate Path Capital
New York
|
-$55.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$26.1M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$18.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$14.6M |
| 5 |
Dodge & Cox
San Francisco,
California
|
-$13.6M |
ALNY Hedge Fund Activity: Q2 2017 in Review
226 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2017, worth a combined $6.95B — up 65% from $4.22B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ALNY positions and 22 closed out — a net gain of 30 holders — while 76 added to existing stakes and 64 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $160M. The largest seller was Slate Path Capital, cutting an estimated $55.3M.
- 226 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2017, up from 198 in Q1 2017.
- Funds reported $6.95B of Alnylam Pharmaceuticals stock for Q2 2017, up 65% quarter-over-quarter.
- 52 funds opened new Alnylam Pharmaceuticals positions in Q2 2017 and 22 closed out, a net change of +30 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2017 was T. Rowe Price Associates, an estimated $160M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2017 was Slate Path Capital, an estimated $55.3M sold.
Based on aggregated 13F filings for Q2 2017.